Bard Discontinues Tegress Incontinence Product Due To Postmarket Expense
This article was originally published in The Gray Sheet
Executive Summary
Bard will halt sales of its urinary incontinence bulking agent Tegress while continuing to offer its Contigen collagen-based device, citing excessive costs associated with Tegress' postmarket requirements